anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Children's Treatment Network (CTN)links existing children's services rather than creating a new Centre. The purpose of the evaluation is to compare the effectiveness and efficiency of this service with the usual care that people receive. 500 Children will be randomized to receive either usual care (250) or the co-ordinated, navigated care from CTN (250). The primary question to be addressed is whether the more integrated CTN model of service improves family-centered services, parent mental health, parenting, family function and the quality of the child's life and the families resource needs as well as reduce expenditures for the families' use of all other health and social services compared to the outcomes of usual care alone. What children and families with what characteristics and circumstances most benefit from which approach to the treatment of childhood disability in Simcoe-York? At what cost?

Agencies providing services to children will be evaluated as to how effective their integration of teams are functioning, their partnership with each other and capacity building in the community.
The invention discloses a traditional Chinese medicine navel paste for treating constipation and a preparation method of the traditional Chinese medicine navel paste. The traditional Chinese medicine navel paste for treating constipation is prepared the following traditional Chinese medicine raw materials in percentage by weight: 16%-20% of raw rhubarb, 16%-20% of magnolia officinalis, 16%-20% of honey, 8%-12% of mirabilite, 8%-12% of unripe bitter orange, 8%-12% of Chinese angelica, 4%-8% of radish seed, 3%-5% of cannabis fruit, 3%-5% of bush cherry kernel and 2% of dried orangepeel. The preparation method comprises the following steps: a. crushing the raw rhubarb, the magnolia, the mirabilite, the unripe bitter orange, the Chinese angelica, the radish seed, the cannabis fruit, the bush cherry kernel and the dried orangepeel into powder, and mixing the powder uniformly to obtain a medicinal powder; b. mixing the honey and the medicinal powder into a paste in a proportion of 1:1. c. smearing about 3g of the paste on anti-anaphylaxis rubberized fabric, and then coating with waterproof membrane. The traditional Chinese medicinal navel paste disclosed by the invention is tested by pre-clinical and clinical pharmacodynamics experiment. The traditional Chinese medicinal navel paste disclosed by the invention is easy to use, good in patient compliance, and remarkable in curative effect in the aspect of improving constipation and high in safety. The traditional Chinese medicinal navel stick has the significant functions of benefiting and moving vital energy, supplying and quickening blood circulation, dispersing food and eliminating phlegm, moistening dryness and lubricating intestines.
Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
<P>PROBLEM TO BE SOLVED: To obtain a composition for dentifrice containing calcium hydrogenphosphate, in which monofluorophosphate used as a fluorine source of the composition for the dentifrice is stabilized and its effect is sustained.  <P>SOLUTION: The composition for the dentifrice comprises a fluorophosphates, calcium hydrogenphosphate, a soluble phosphate (except calcium salt) and a magnesium phosphate compound in which the contents of the soluble phosphate and the magnesium phosphate compound are 0.5-5 parts wt. based on 100 parts wt. of calcium hydrogenphosphate. The composition for dentifrice has excellent fluorine stability.  <P>COPYRIGHT: (C)2003,JPO
OBJECTIVE: Bariatric surgery has several benefits, including sustainable weight loss and improvement or resolution of metabolic comorbidities. However, despite initially successful weight loss, weight regain occurs during long-term follow-up, and many patients are unable to reach or maintain their target weight goals. Liraglutide is a therapy for obesity aimed at preventing weight regain.
MATERIALS AND METHODS: This retrospective, observational, single-arm, pre-post study was performed to analyze the relative change in body weight among patients receiving liraglutide after bariatric surgery in a real-world setting in Chile.
RESULTS: Treatment with liraglutide at a median dose of 1.2 mg was associated with a mean weight loss from baseline to 3, 6, 12, 24, and 36 months of 5%, 7.7%, 7.6%, 5.8%, and 5.1%, respectively. The mean body mass index reduction was 14.8% at 36 months. Dropout rates were consistent with those of usual obesity treatments. Overall, 70% of the patients were receiving other weight-loss drugs. Liraglutide was well tolerated, but cost barriers led to several patients interrupting its use.
CONCLUSION: Liraglutide is an effective and safe treatment for weight reduction after bariatric surgery in patients receiving routine clinical care in Chile.
The clinical efficacy and safety of desloratadine tablets 5 mg were evaluated in over 1300 patients 12 to 80 years of age with perennial allergic rhinitis. A total of 685 patients received 5 mg/day of desloratadine in two double-blind, randomized, placebo-controlled clinical trials of 4 weeks' duration conducted in the United States and internationally. In one of these studies desloratadine tablets 5 mg once daily was shown to significantly reduce the Total Symptom Score in patients with perennial allergic rhinitis (Table 4).

*At baseline, average of total symptom score (sum of 5 individual nasal symptoms and 3 non-nasal symptoms, each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) of at least 10 was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms.

†Mean reduction in TSS averaged over the 4 week treatment period.
PURPOSE:To prevent or treat urinary calculus of pets such as dogs, cats or small animals by a pharmaceutical preparation having high palatability and free from side effects. CONSTITUTION:This method for treating urinary calculus of pets is to administer or feed a pharmaceutical preparation or a pet food containing an edible carboxylic acid such as fumaric acid or its salt, an edible oxycarboxylic acid or its salt to pets. The content of the edible organic acid or its salt is about 0.1-99.9wt.% in the case of a pharmaceutical preparation such as a solid pharmaceutical preparation and about 0.01-10wt.% in the case of pet food such as dry food, expressed in terms of edible organic acid. The dose of the edible organic acid or its salt is about 5-500mg/kg weight. day, expressed in terms of the edible organic acid. Since the pharmaceutical preparation has high palatability and safety, compared with a conventional urine-acidifying agent, urinary calculus of pets can be prevented and treated in small doses or feed amounts.
<P>PROBLEM TO BE SOLVED: To obtain a detergent, such as a shampoo or a body soap, capable of abundantly foaming when practically used at home.  <P>SOLUTION: This detergent, e.g. the shampoo, contains microcapsules 1. The microcapsules 1 contain a foaming agent 2 enclosed therein and are ruptured under a pressure in use (e.g. a pressure at a nozzle of a detergent container or a pressure by hand in bubbling the detergent by man); hence, the foaming agent 2 is activated and foams, thus bubbling the detergent.  <P>COPYRIGHT: (C)2004,JPO
Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Levodopa is the most effective symptomatic treatment; however, long term use is associated with motor fluctuations (periods of return of PD symptoms when medication effect wears off) and dyskinesia (drug induced involuntary movements including chorea and dystonia). Once patients develop motor fluctuations treatment options include increasing the frequency of levodopa dosing, switching to sustained-release levodopa, adding other therapies including monoamine oxidase type B (MAO-B) inhibitors, dopamine agonists, catechol-o-methyltransferase (COMT) inhibitors and in patients with severe motor fluctuations deep brain stimulation surgery. There are no good evidence based studies indicating whether the use of one of these class of drugs is superior to the other nor are there treatment algorithms that recommend which class of drug should be initiated when the patients initially develop motor fluctuations. It is believed that the efficacy of the different drug classes is similar. However, the frequency of adverse effects may differ between drug classes, but such studies are lacking. In clinical practice when patients develop adverse effects to a drug from one class, a drug from another class is substituted in an attempt to maintain efficacy with reduced adverse effects.

Dopamine agonists often have a higher risk of adverse effects compared to MAO B inhibitors. Therefore, the rationale for this study is that the addition of orally disintegrating selegiline after the reduction or discontinuation of the offending dopamine agonist will result in comparable efficacy with reduced adverse events. This study will assess the safety and efficacy of the addition of orally disintegrating selegiline in PD patients who are having adverse effects to dopamine agonists for which a dose reduction of the dopamine agonist is being considered. All patients in the study will receive orally disintegrating selegiline 1.25 mg once a day and the dose will be increased to 2.5 mg once a day if tolerated.

Comparisons: The status of the adverse event at the end of the study while on orally disintegrating selegiline will be compared to the adverse event at the start of the study. In addition, efficacy will be compared at the start of the study while on the dopamine agonist to the end of the study with orally disintegrating selegiline.
This study intended to collect MRI of Patients with Multilevel Cervical Spondylotic Myelopathy. K-line(-) patients can be performed LAMP surgery for better prognosis if mK-line(+) and TypeⅠSC-line in MRI, but there are doubts on TypeⅡ and TypeⅢ. However, there has been no study that investigated the combination role of the mK-line and SC-line in surgical decision making for patients with MCSM. In this study, the investigators defined mK-line as a straight line connecting the midpoints of the anteroposterior canal diameter at cranial and caudal vertebrae of the open-door segment in MRI. Accordingly, the investigators propose a modified spinal cord line(mSC-line) that is a straight line connecting the postero-inferior point of the spinal cord at cranial and caudal vertebrae of the open-door segment in MRI, and simplify the mSC-line types into mSC-line(+) and mSC-line(-). In other words, mK-line and mSC-line in MRI are not fixed, but vary depending on the preoperative open-door segments. This study included patients with LAMP surgery for follow up, whose mK-line and mSC-line in MRI were double-positive for preoperative deciding open-door segments.
The present invention relates to liquid membrane capsules which rupture when contacted with biliary or pancreatic secretions in the intestine thereby releasing their contents in the intestine so the contents become fully available for the treatment of disease at that location in the animal or patient. Particularly, the rupturable liquid membrane capsules containing urease are used for the treatment of chronic uremia. The liquid membrane capsules comprise an internal aqueous phase which contains an oil insoluble medicinal of choice, some complexing agent, dietary supplement or enzyme particularly suited for the intended treatment. This internal aqueous and oil insoluble phase is encapsulated in a nonaqueous external phase comprising a biologically inert oil component, and a material which will complex with the biliary and/or pancreatic secretions in the intestine thereby causing the rupture of the external phase resulting in the release of the internal phase in the intestine. Thus, the internal phase is isolated during passage through the mouth, esophagus, and stomach. On the absence of this isolation the material might be an irritant or be degraded in some of these areas. 
     The invention is further related to a method of in vivo detoxification comprising the use of liquid membrane capsules containing detoxification materials such as medicinals and/or enzymes as an aqueous internal phase encapsulated in a continuous external phase comprising an oil which external phase further contains an additive which complexes with the biliary and/or pancreatic secretions in the intestine causing the rupture of the external phase, the detoxification process proceeding by the rupture of the external phase resulting in the release of the internal phase in the intestine. The internal phase in this case is such that it will bring about a conversion of certain toxins in the intestine to forms that can readily be trapped by conventional toxin trapping LMC as described by prior art.
Patients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
Achieving hemostasis in penetrating and irregular wounds is challenging because the hemostasis factor cannot arrive at the bleeding site, and substantial bleeding will wash away the blood clot. Since the inherently gradual nature of blood clot formation takes time, a physical barrier is needed before blood clot formation. Herein, an ultra-light and shape memory hemostatic aerogel consisting of oxidized bacterial cellulose (OBC) and platelet extracellular vesicles (pVEs) is reported. The OBC-pVEs aerogel provides a physical barrier for the bleeding site by self-expansion, absorbing the liquid from blood to concentrate platelets and clotting factors and accelerating the clot formation by activating platelets and transforming fibrinogen into fibrin. In the rat liver and tail injury models, the blood loss decreases by 73% and 59%, and the bleeding times are reduced by 55% and 62%, respectively. OBC-pVEs aerogel has also been shown to accelerate wound healing. In conclusion, this work introduces an effective tool for treating deep, non-compressible, and irregular wounds and offers valuable strategies for trauma bleeding and wound treatment.
A 2-year-old neutered male Bengal cat presented with solid food dysphagia and chronic regurgitation for >5 months. There were no clinical abnormalities on haematological or radiographic examinations. Thoracic radiography revealed a soft tissue opacity mass adjacent to the diaphragm in the caudoventral thorax. Ultrasonography revealed a protruding liver lobe surrounded by a hyperechoic lining from the diaphragm towards the thorax, and a pleuroperitoneal hernia was diagnosed. An endoscopy was performed to examine the cause of regurgitation, and an oesophageal stricture was observed. Endoscopic balloon dilation of the oesophageal stricture was performed, and the regurgitation was resolved immediately. However, regurgitation relapsed 2 months later, and computed tomography was performed to ascertain the cause. Computed tomography revealed oesophageal mural thickening and true pleuroperitoneal hernia with partial liver lobe herniation. A second endoscopy with balloon dilation was performed to treat the relapsing oesophageal stricture, and the clinical signs resolved without the need for herniorrhaphy. Nevertheless, oesophageal stricture could occur due to gastroesophageal reflux related to a pleuroperitoneal hernia; however, a definite link could not be elucidated in this case. This report describes a case of oesophageal stricture and concurrent true pleuroperitoneal hernia in a cat.
Introduction: Complex regional pain syndrome type I (CRPS-I) is a debilitating neuropathic painful condition associated with allodynia, hyperalgesia, sudomotor and/or vasomotor dysfunctions, turning investigation of its pathophysiology and new therapeutic strategies into an essential topic. We aim to investigate the impact of ischemia/reperfusion injury on the immunocontent of CB1 and CB2 cannabinoid receptor isoforms in the paws of mice submitted to a chronic postischemia pain (CPIP) model and the effects of local administration of cannabidiol (CBD) on mechanical hyperalgesia. Methods: Female Swiss mice, 30-35 g, were submitted to the CPIP model on the right hind paw. Skin and muscle samples were removed at different periods for western blot analysis. Results: No changes in the immunocontent of CB1 and CB2 receptors in paw muscle tissues after ischemia-reperfusion were observed. CBD promoted an antihyperalgesic effect in both phases. AM281 reversed the effect of CBD, whereas ruthenium red abolished the late phase. Conclusion: Our results point to the possible beneficial effects of local administration of CBD in modulating CRPS-I in humans. As possible targets for CBD antihyperalgesia in this model, the contribution of cannabinoid receptor CB1, in addition to TRPM8 is suggested.
SARS-CoV-2 provokes devastating tissue damage by cytokine release syndrome and leads to multi-organ failure. Modeling the process of immune cell activation and subsequent tissue damage is a significant task. Organoids from human tissues advanced our understanding of SARS-CoV-2 infection mechanisms though, they are missing crucial components: immune cells and endothelial cells. This study aims to generate organoids with these components. We established vascular immune organoids from human pluripotent stem cells and examined the effect of SARS-CoV-2 infection. We demonstrated that infections activated inflammatory macrophages. Notably, the upregulation of interferon signaling supports macrophages' role in cytokine release syndrome. We propose vascular immune organoids are a useful platform to model and discover factors that ameliorate SARS-CoV-2-mediated cytokine release syndrome.
PURPOSE:To provide the subject porous spherular powder exhibiting a high-water diffusion rate and a suitable oil absorption and capable of producing a cosmetic excellent in spreading on the skin, feeling in use and durability of make up effect. CONSTITUTION:The objective pressure-non-collapsible porous spherular powder having 10 to 200mum average particle size and >=0.4cm<3>/g total pore volume is obtained by using one or more kinds of materials selected from a water-soluble polymer, a hydrophobic polymer and an inorganic colloid solution as a binder and granulating powder for cosmetics, preferably spherular powder having 0.1 to 10mum average particle size and 1 to 800m<2>/g specific surface area according to the spray drying method using a spray dryer of disk type, nozzle type, etc. In the above-mentioned granulation, the above-mentioned binder is blended preferably in an amount of 5 to 50 pts.wt., especially 10 to 30 pts.wt. based on 100 pts.wt. powder. A cosmetic containing the above-mentioned porous spherular powder can let sweat secreted from the skin with time escape, suitably absorb sebum and, therefore, maintain its make up effect.
FIELD: medicine, narcology. SUBSTANCE: triple-protection method for treatment of alcoholism consists in that curative effect is directed to the three points of alcoholism etiopathogenesis:treatment of syndrome of morbid attraction to alcohol; metalcohol toxicosis, system alcohol encephalopathy and visceropathy; psychical disturbances. The method consists in successive integrated curative effect. At the first stage, preparation ESPERAL is administered by 0.25 g two times a day for 5-10 days. At the second stage, psychosuggestive action in the awake state is offered. At the third stage, infusion of medicinal herbs is administered for 21 days by 100 ml, three times a day in 20 min before meal. The offered method is recommended for treatment of patients ill with alcoholism of 2nd and 3d stages. EFFECT: higher efficiency.
A method for presenting insulin therapy setting recommendations associated with a therapy insight for a person with diabetes (PWD) at an electronic device. The method includes, at a device with one or more processors, memory, and a display, displaying on a dashboard of a PWD, at the display a first layer. The first layer includes a therapy insight corresponding to a PWD. The therapy insight generated based in part on insulin therapy data of the PWD. The therapy insight corresponds to insulin therapy of the PWD. The therapy insight comprises clinical advice for insulin-based management of PWDs diabetes. The first layer also includes an insulin therapy recommendation associated with the therapy insight. The insulin therapy recommendation corresponds to a pattern of behavior associated with the insulin-based management of the PWDs diabetes wherein the first layer overlays at least a portion of a second layer. The first layer overlays at least a portion of a second layer.
PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m\^2)) was administered on Day 2 of each 21-day cycle.
The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
Alcohol is a substance that impacts premature mortality and morbidity.1 The liver is invariably subjected to the impact of alcohol, which can result in cirrhosis and cancer. Alcohol also has detrimental effects that extend beyond the liver. While traditionally associated with advanced age, emerging data reported a rising burden of cancers and alcohol-associated liver disease in the young.1-3 Thus, the primary objective was to evaluate the trend of alcohol-associated cirrhosis and cancer in young and middle-aged adults (aged 15-49) utilizing the Global Burden of Disease Study (GBD) 2019.4 We chose the age group less than 50 years old based on the definition of early-onset cancer and the inherent selection of the age group in the GBD database.4-6 The detailed methods are provided in the Supplementary Appendix. Briefly, data were sourced from population-based cancer registries, vital registration systems, or verbal autopsy studies. Verbal autopsy is a well-established approach for monitoring health, providing valuable information on mortality patterns and the reasons behind deaths in areas lacking robust medical death certification processes. The researchers employed the Cause of Death Ensemble model to estimate the burden linked to cancer and cirrhosis associated with alcohol use.